ISOPRINOSINE Inosine Acedoben Dimepranol 250mg / 5mL Syrup 60mL Cherry

Indications/Uses

For the treatment of various infections such as: Herpes simplex, Genital warts, Sclerosing panencephalitis.

Dosage/Direction for Use

Syrup Dosage: Initially and during the peak stage of the disease: 100 mg/kg body weight daily.
Subsequently, 50 mg/kg body weight daily as maintenance. (See table.)

Adults: 2-teaspoonfuls, 6-8 times daily.
Tablet Dosage: Adults: 6-8 tablets daily in divided doses.
Children: 3-4 tablets in divided doses.
Treatment Duration: Acute viral diseases of short evolution - treatment should continue one to two days after symptoms subside, or longer, according to the doctor's judgment.
Acute viral diseases of long evolution - treatment should continue one to two weeks after symptoms subside, or longer, according to the doctor's judgment. This is to avoid relapses.
ISOPRINOSINE may be administered simultaneously with other chemotherapeutics, such as antibiotics, as it shows no drug incompatibilities.

Administration

Should be taken with food.

Special Precautions

ISOPRINOSINE should be used with caution in gout or renal disturbances as it may increase uric acid concentrations. For its slight cardiac effect, administration to digitalised patients should be closely supervised. Finally, the use of any drug in pregnancy, lactation or in women of childbearing age requires that its potential benefits be weighed against its possible hazards.

Use In Pregnancy & Lactation

The use of any drug in pregnancy, lactation or in women of childbearing age requires that its potential benefits be weighed against its possible hazards.

Adverse Reactions

ADR Reporting Statement: Please seek medical attention immediately at the first sign of any adverse drug reaction.

Storage

Store at temperatures not exceeding 30°C.

Action

Pharmacology: ISOPRINOSINE ACTS IN TWO WAYS: First: One of the most important natural defenses against virus diseases is immunity. Vaccines work to prevent virus diseases if given before onset of the disease.
Unfortunately, vaccines do not work therapeutically after onset of the disease.
ISOPRINOSINE works to enhance the natural immune response of lymphocytes when given after the onset of virus diseases.
Second: Viruses interfere with cellular protein and nucleic acid synthesis and force the cell to produce viral nucleic acid and proteins. In this manner the viruses reproduces, preserves its pathogenic power and distributes its progeny in the infected organism.
ISOPRINOSINE has a specific action on ribosomes and polyribosomes, preserving their structure and function, and transmitting to them at the same time a resistance to any foreign genetic information.
ISOPRINOSINE while preserving the structure and function of the polyribosomes, impedes the DNA or RNA of the virus from transmitting its own genetic code. It preserves the normal protein synthesizing mechanism and prevents the virus from multiplying in the organism.
Taken orally, ISOPRINOSINE is absorbed within 20 minutes and appears with its metabolites rapidly in the blood and urine.
Experiments have been made with C-14 labelled ISOPRINOSINE to determine distribution and metabolism in plasma, organs and urine in cats, rats and monkeys. It was found that absorption was rapid, and that the drug remains in the blood for 3-6 hours, with the highest concentration between the 2nd and 3rd hr. Accumulation, however, does not occur since it is rapidly eliminated with its metabolites in the urine. Chromatographic studies revealed the following metabolites: inosine monophosphate, guanosine monophosphate, adenosine monophosphate, inosine, guanine, adenine, xanthosine, hypoxanthine, xanthine, uric acid, and allantoin.
All these compounds found in plasma, urine and organs represent normal components of purine metabolism and are not considered toxic.
Toxicology: The therapeutic to toxic dose ratio is 1:100, thus ISOPRINOSINE is very safe. The experiments with animals have revealed that the dose which produces signs and symptoms of toxicity, ranges from 4,000 to 10,000 mg/kg in rats, mice, guinea pigs and monkeys. Rhesus monkeys received 500 mg/kg daily for 104 weeks and showed no biochemical or hispathological change.
In volunteer humans the administration of up to 6 g daily for periods of 6 months up to 4 years produced no modifications in the biochemical, electrocardiographic or encephalographic analyses, except for moderate increases in the serum uric acid levels. Animal experimentation has indicated the lack of any teratogenic effects.

MedsGo Class

Antivirals